Wang Lan, Zhou Guang-Biao, Liu Ping, Song Jun-Hong, Liang Yang, Yan Xiao-Jing, Xu Fang, Wang Bing-Shun, Mao Jian-Hua, Shen Zhi-Xiang, Chen Sai-Juan, Chen Zhu
State Key Laboratory of Medical Genomics and Shanghai Institute of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Road II, Shanghai 200025, China.
Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4826-31. doi: 10.1073/pnas.0712365105. Epub 2008 Mar 14.
To enhance therapeutic efficacy and reduce adverse effects, practitioners of traditional Chinese medicine (TCM) prescribe a combination of plant species/minerals, called formulae, based on clinical experience. Nearly 100,000 formulae have been recorded, but the working mechanisms of most remain unknown. In trying to address the possible beneficial effects of formulae with current biomedical approaches, we use Realgar-Indigo naturalis formula (RIF), which has been proven to be very effective in treating human acute promyelocytic leukemia (APL) as a model. The main components of RIF are realgar, Indigo naturalis, and Salvia miltiorrhiza, with tetraarsenic tetrasulfide (A), indirubin (I), and tanshinone IIA (T) as major active ingredients, respectively. Here, we report that the ATI combination yields synergy in the treatment of a murine APL model in vivo and in the induction of APL cell differentiation in vitro. ATI causes intensified ubiquitination/degradation of promyelocytic leukemia (PML)-retinoic acid receptor alpha (RARalpha) oncoprotein, stronger reprogramming of myeloid differentiation regulators, and enhanced G(1)/G(0) arrest in APL cells through hitting multiple targets compared with the effects of mono- or biagents. Furthermore, ATI intensifies the expression of Aquaglyceroporin 9 and facilitates the transportation of A into APL cells, which in turn enhances A-mediated PML-RARalpha degradation and therapeutic efficacy. Our data also indicate A as the principal component of the formula, whereas T and I serve as adjuvant ingredients. We therefore suggest that dissecting the mode of action of clinically effective formulae at the molecular, cellular, and organism levels may be a good strategy in exploring the value of traditional medicine.
为提高治疗效果并减少不良反应,中医从业者根据临床经验开出植物物种/矿物质的组合,即方剂。已记录了近10万种方剂,但大多数的作用机制仍不清楚。为了用当前的生物医学方法探究方剂可能的有益效果,我们使用已被证明在治疗人类急性早幼粒细胞白血病(APL)方面非常有效的雄黄-青黛方(RIF)作为模型。RIF的主要成分是雄黄、青黛和丹参,其中四硫化四砷(A)、靛玉红(I)和丹参酮IIA(T)分别为主要活性成分。在此,我们报告ATI组合在体内治疗小鼠APL模型以及体外诱导APL细胞分化方面产生协同作用。与单一或二元药物的作用相比,ATI通过作用于多个靶点导致早幼粒细胞白血病(PML)-维甲酸受体α(RARα)癌蛋白的泛素化/降解增强、髓系分化调节因子的重编程更强以及APL细胞中G(1)/G(0)期阻滞增强。此外,ATI增强水甘油通道蛋白9的表达并促进A进入APL细胞,这反过来增强了A介导的PML-RARα降解和治疗效果。我们的数据还表明A是该方剂的主要成分,而T和I作为辅助成分。因此,我们建议在分子、细胞和生物体水平剖析临床有效方剂的作用模式可能是探索传统医学价值的一个好策略。